Evaluation of a New Therapeutic Option for Mast Cell Tumors |
Trial Eligibility Criteria Includes:
• Dogs with measurable cutaneous mast cell tumor(s).
• Mast cell tumor histological grade II or III.
• Dogs in whom curative intent surgery cannot be performed or has been declined by the owner.
• Regional lymph node involvement accepted.
• Dogs at any age, weight, gender, breed with satisfactory health: must be at least 5kg.
• No prior chemotherapy.
• No radiation therapy to a target lesion. If prior radiation therapy is performed, a 3-week washout is required before study enrollment.
• Three-week washout period for prednisone, 2-week washout period for non-steroidal anti-inflammatory drugs.
Trial Support and Funding:
There is no placebo included in this trial. Dogs will be randomized 2:1 to initially receive the new investigational drug or an active chemotherapeutic against mast cell tumors, lomustine. The initial consultation fee must be paid by the owner. Once an informed consent form is signed, all diagnostic tests, study drug, follow-up evaluations, and management of potential side effects will be paid for by the study.
| 
